Proteasome inhibitor bortezomib overcomes P-gp-mediated multidrug resistance in resistant leukemic cell lines

International Journal of Laboratory Hematology

Volumn 34, Issue 3, 2012, Pages 237-247

  Zheng, B ^a   Zhou, R ^a   Gong, Y ^a   Yang, X ^a   Shan, Q ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Apoptosis; Bortezomib; Drug resistance; Leukemia cell line; Multifactor drug resistance; P glycoprotein; Single factor drug resistance

Indexed keywords

BORTEZOMIB; DAUNORUBICIN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN BCL 2; VERAPAMIL;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER INHIBITION; CANCER PATIENT; CANCER RESISTANCE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG EXPOSURE; DRUG POTENTIATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

APOPTOSIS; BORONIC ACIDS; CELL LINE, TUMOR; CELL PROLIFERATION; DAUNORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENZYME INHIBITORS; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; K562 CELLS; LEUKEMIA; P-GLYCOPROTEIN; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZINES;

EID: 84860234630     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1751-553X.2011.01384.x     Document Type: Article

References (26)

1. Armstrong M.B., Schumacher K.R., Mody R., Yanik G.A., Opipari Jr A.W. & Castle V.P. (2008) Bortezomib as a therapeutic candidate for neuroblastoma. Journal of Experimental Therapeutics and Oncology 7, 135-145.
2. Attar E.C., Learner E. & Amrein P.C. (2004) In vitro studies of bortezomib with daunorubicin and cytarabine: sequence of administration affects leukemia cell chemosensitivity. Blood (ASH Annual Meeting Abstracts) 104: [Abstract 4464].
3. Breccia M. & Alimena G. (2010) NF-κB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia. Expert Opinion on Therapeutic Targets 14, 1157-1176.
4. Bruserud Ø. & Reikvam H. (2010) Therapeutic targeting of NF-κB in myelodysplastic syndromes and acute myeloid leukeaemia-the biological heterogeneity. Expert Opinion on Therapeutic Targets 14, 1139-1142.
5. Choi C.H. (2005) ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell International 5, 30.
6. Cornwell M.M., Pastan I. & Gottesman M.M. (1987) Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. Journal of Biological Chemistry 262, 2166-2170.
7. Fennell D.A., Chacko A. & Mutti L. (2008) Bcl-2 family regulation by the 20S proteasome inhibitor bortezomib. Oncogene 27, 1189-1197.
8. Gong Y., Wang Y., Chen F., Han J., Miao J., Shao N., Fang Z. & Ou Yang R. (2000) Identification of the subcellular localization of daunorubicin in multidrug-resistant K562 cell line. Leukemia Research 75, 769-774.
9. Horton T.M., Gannavarapu A., Blaney S.M., D'Argenio D.Z., Plon S.E. & Berg S. (2006) Brotezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemotherapy and Pharmacology 58, 13-23.
10. Ishii Y., Waxman S. & Germain D. (2007) Targeting the ubiquitin-proteasome pathway in cancer therapy. Anti-Cancer Agents in Medicinal Chemistry 7, 359-365.
11. Kobayashi H., Takemura Y., Kawai Y., Miyachi H., Kawabata M., Matsumura T., Yamashita T., Mori S., Furihata K., Shimodaira S., Motoyoshi K., Hotta T., Sekiguchi S., Ando Y. & Watanabe K. (2000) Competitive reverse transcription-polymerase chain reaction assay for quantification of human multidrug resistance 1 (MDR1) gene expression in fresh leukemic cells. Journal of Laboratory Clinical Medicine 135, 199-209.
12. Leonard J.P., Furman R.R. & Coleman M. (2006) Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma. International Journal of Cancer 119, 971-979.
13. Ling Y.H., Liebes L., Jiang J.D., Holland J.F., Elliott P.J., Adams J., Muggia F.M. & Perez-Soler R. (2003) Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clinical Cancer Research 9, 1145-1154.
14. Lu G., Punj V. & Chaudhary P.M. (2008) Proteasome inhibitor Bortezomib induces cell cycle arrest and apoptosis in cell lines derived from Ewing's sarcoma family of tumors and synergizes with TRAIL. Cancer Biology & Therapy 7, 603-608.
15. Lü S., Chen Z., Yang J., Chen L., Zhou H., Xu X., Li J., Han J. & Wang J. (2010) The effects of proteasome inhibitor bortezomib on a P-gp positive leukemia celll ine K562/A02. International Journal of Laboratory Hematology 32, e123-e131.
16. Marie J.P. (2001) Drug resistance in hematologic malignancies. Current Opinion in Oncology 13, 463-469.
17. Mitsiades C.S., Treon S.P., Mitsiades N., Shima Y., Richardson P., Schlossman R., Hideshima T. & Anderson K.C. (2001) TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 98, 795-804.
18. Mitsiades N., Mitsiades C.S., Richardson P.G., Poulaki V., Tai Y.T., Chauhan D., Fanourakis G., Gu X., Bailey C., Joseph M., Libermann T.A., Schlossman R., Munshi N.C., Hideshima T. & Anderson K.C. (2003) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101, 2377-2380.
19. Motoji T., Motomura S. & Wang Y.H. (2000) Multidrug resistance of acute leukemia and a strategy to overcome it. International Journal Of Hematology 72, 418-424.
20. Muller C., Bailly J.D., Goubin F., Laredo J., Jaffrézou J.P., Bordier C. & Laurent G. (1994) Verapamil decreases P-glycoprotein expression in multidrug-resistant human leukemic cell lines. International Journal of Cancer 56, 7492-7541.
21. Nandi D., Tahiliani P., Kumar A. & Chandu D. (2006) The ubiquitin-proteasome system. Journal of Biosciences 31, 137-155.
22. Rumpold H., Salvador C., Wolf A.M., Tilg H., Gastl G. & Wolf D. (2007) Knockdown of Pgp resensitizes leukemic cells to proteasome inhibitors. Biochemical and Biophysical Research Communications 361, 549-554.
23. Stapnes C., Døskeland A.P., Hatfield K., Ersvær E., Ryningen A., Lorens J.B., Gjertsen B.T. & Bruserud Ø. (2007) The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. British Journal of Haematology 136, 814-828.
24. Sterz J., von Metzler I., Hahne J.C., Lamottke B., Rademacher J., Heider U., Terpos E. & Sezer O. (2008) The potential of proteasome inhibitors in cancer therapy. Expert Opinion on Investigational Drugs 17, 879-895.
25. Tan Y.H., Yang C.Z., Zhao C.H., Qi J., Peng H., Wang J.X., Zhou Y., Xiao Y. & Lan L. (2004) Identification of differentially expressed genes involved in multidrug resistance in K562/A02 by cDNA microarray. Zhonghua Zhong Liu Za Zhi 26, 328-332.
26. Ye X., Liu T., Gong Y., Zheng B., Meng W. & Leng Y. (2009) Lentivirus-mediated RNA interference reversing the drug-resistance in MDR1 single-factor resistant cell line K562/MDR1. Leukemia Research 33, 1114-1119.